Every night, the online Belgian patent register ('eRegister') receives an update with public data that were entered or generated the preceding day on the Benelux Patent Platform, the computer application with which the Belgian Intellectual Property Office handles the registration, treatment and publication processes for patents and supplementary protection certificates.
Currently, some updates are spread over consecutive nights due to the large, weekly volume of data concerning European patents designating Belgium.
For a European patent it is possible that data about the inventor(s) are missing from the online Belgian patent register. They can be found via the link to the European patent register pending an update of the Belgian patent register.
For European patents with Unitary Effect, the authentic source of information is the European Patent Register : please refer to it.

Patent details

2025C511 Product name: cellules autologues CD3+ transduites anti-CD19 (brexucabtagene autoleucel)

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic information

Application number:
2025C/511
Type:
Certificate
SPC type:
Medical
Basic patent number:
157463993
Status:
Open & Published
Publication number:
2025C511
1rst applicant's nationality:
Procedural language:
French

Marketing authorization

Marketing authorization number:
EU/1/20/1492
Marketing authorization type:
National/EU
Designates country:
No
Marketing authorization date:
15/12/2020
Marketing authorization status:
Accepted
Marketing authorization country:
Belgium (BE)

Dates

Filing date:
24/02/2025
First marketing authorization date:
15/12/2020
Grant date:
Activation date:
BE Publication date:
05/03/2025
Lapsed date:
Expiration date (if granted and all annual fees paid):
Basic SPC Expiration (if granted and all annual fees paid):
15/12/2035
SPC/SPC Extension Expiration (if granted and all annual fees paid):
Rejection date:
Withdrawal date:

Applicant

1

Name:
The United States of America, as Represented by The Secretary, Department of Health and Human Services
Legal Form:
Département du Gouvernement des Etats-Unis
From:
25/02/2025
Address:
Office of Technology Transfer National Institutes of Health 6701 Rockledge Drive Suite 700, MSC 7788, Bethesda, Maryland 20892-7788, United States (US)
To:

2

Name:
Kite Pharma, Inc.
Legal Form:
corporation
From:
25/02/2025
Address:
2400 Broadway, Santa Monica, CA 90404, United States (US)
To:

Agent

Name:
KIRKPATRICK
Legal Form:
S.A.
From:
25/02/2025
Address:
Avenue Wolfers 32, 1310, LA HULPE, Brabant wallon, Belgium (BE)
To:

Publication

Bulletin

Bulletin heading:
SPC
Journal edition number:
2025/05
Publication date:
05/06/2025
Description:
Contains data concerning applications for- or granted Supplementary Protection Certificates
Filing date Document type Publication Type Document Description Number of pages File Type
24/02/2025 Application Form 5 PDF /9/7/0/2/1/0722512079/docs/2025c511_0_applicationform_20250225_084522788.pdf
24/02/2025 MA Official Publication Official Publication of 1st Marketing Authorization 10 PDF /9/7/0/2/1/0722512079/docs/2025c511_1_maofficialpublication_20250225_084522514.pdf
24/02/2025 Marketing Authorization 1st Marketing Authorization (EU) 4 PDF /9/7/0/2/1/0722512079/docs/2025c511_2_marketingauthorization_20250225_084522697.pdf
24/02/2025 General Document Other 7 PDF /9/7/0/2/1/0722512079/docs/2025c511_3_generaldocument_20250225_084521572.pdf
24/02/2025 General Document Other 3 PDF /9/7/0/2/1/0722512079/docs/2025c511_4_generaldocument_20250225_084520801.pdf
24/02/2025 Abstract Product Characteristics Abstract of the characteristics of the product 43 PDF /9/7/0/2/1/0722512079/docs/2025c511_5_abstractproductcharacteristics_20250225_084522387.pdf
24/02/2025 General Document Other 14 PDF /9/7/0/2/1/0722512079/docs/2025c511_6_generaldocument_20250225_084520935.pdf
24/02/2025 General Document Other 13 PDF /9/7/0/2/1/0722512079/docs/2025c511_7_generaldocument_20250225_084521882.pdf
24/02/2025 General Document Other 39 PDF /9/7/0/2/1/0722512079/docs/2025c511_8_generaldocument_20250225_084521644.pdf
24/02/2025 General Document Other 8 PDF /9/7/0/2/1/0722512079/docs/2025c511_9_generaldocument_20250225_084521502.pdf
24/02/2025 General Document Other 131 PDF /9/7/0/2/1/0722512079/docs/2025c511_10_generaldocument_20250225_084521161.pdf
24/02/2025 General Document Other 127 PDF /9/7/0/2/1/0722512079/docs/2025c511_11_generaldocument_20250225_084520447.pdf
24/02/2025 General Document Other 21 PDF /9/7/0/2/1/0722512079/docs/2025c511_12_generaldocument_20250225_084520267.pdf
24/02/2025 General Document Other 5 PDF /9/7/0/2/1/0722512079/docs/2025c511_13_generaldocument_20250225_084520154.pdf
24/02/2025 General Document Other 38 PDF /9/7/0/2/1/0722512079/docs/2025c511_14_generaldocument_20250225_084522194.pdf
24/02/2025 General Document Other 3 PDF /9/7/0/2/1/0722512079/docs/2025c511_15_generaldocument_20250225_084522079.pdf
05/03/2025 Publication I1 1 PDF /9/7/0/2/1/0722512079/docs/2025c511_16_i1document_20250305_093648112.pdf
05/03/2025 Outgoing Correspondence 2 PDF /9/7/0/2/1/0722512079/docs/2025c511_17_outgoingcorrespondence_20250305_034702631.pdf